These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
311 related articles for article (PubMed ID: 21375166)
41. Drug-eluting balloons in the treatment of de-novo coronary lesions: a meta-analysis of randomized-controlled trials. Li Y; Wang C; Zuo G; Wang K; Cao Z; Du X Coron Artery Dis; 2016 Sep; 27(6):467-77. PubMed ID: 27100660 [TBL] [Abstract][Full Text] [Related]
42. Paclitaxel-coated balloon with bare-metal stenting in patients with chronic total occlusions in native coronary arteries. Wöhrle J; Werner GS Catheter Cardiovasc Interv; 2013 Apr; 81(5):793-9. PubMed ID: 22511572 [TBL] [Abstract][Full Text] [Related]
43. Comparative assessment of the antirestenotic efficacy of two paclitaxel drug-eluting balloons with different coatings in the treatment of in-stent restenosis. Nijhoff F; Stella PR; Troost MS; Belkacemi A; Nathoe HM; Voskuil M; Samim M; Doevendans PA; Agostoni P Clin Res Cardiol; 2016 May; 105(5):401-11. PubMed ID: 26541146 [TBL] [Abstract][Full Text] [Related]
44. Preliminary results of the hydroxyapatite nonpolymer-based sirolimus-eluting stent for the treatment of single de novo coronary lesions a first-in-human analysis of a third-generation drug-eluting stent system. Costa JR; Abizaid A; Costa R; Feres F; Tanajura LF; Abizaid A; Mattos LA; Staico R; Siqueira D; Sousa AG; Bonan R; Sousa JE JACC Cardiovasc Interv; 2008 Oct; 1(5):545-51. PubMed ID: 19463357 [TBL] [Abstract][Full Text] [Related]
45. Prospective, large-scale multicenter trial for the use of drug-coated balloons in coronary lesions: The DCB-only All-Comers Registry. Rosenberg M; Waliszewski M; Chin K; Ahmad WAW; Caramanno G; Milazzo D; Nuruddin AA; Liew HB; Maskon O; Aubry P; Poyet R; Frey N Catheter Cardiovasc Interv; 2019 Feb; 93(2):181-188. PubMed ID: 30280482 [TBL] [Abstract][Full Text] [Related]
46. Safety and efficacy of drug-eluting balloons in the treatment of drug-eluting in-stent restenosis: experience of a tertiary care hospital. Dhakam S; Jafferani A; Ahmed H; Rahman N; Gowani A J Invasive Cardiol; 2012 Jul; 24(7):335-8. PubMed ID: 22781472 [TBL] [Abstract][Full Text] [Related]
47. Impact of Paclitaxel-Eluting Balloons Compared to Second-Generation Drug-Eluting Stents for of In-Stent Restenosis in a Primarily Acute Coronary Syndrome Population. Marquis-Gravel G; Matteau A; Potter BJ; Gobeil F; Noiseux N; Stevens LM; Mansour S Arq Bras Cardiol; 2017 Oct; 109(4):277-283. PubMed ID: 28977052 [TBL] [Abstract][Full Text] [Related]
48. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial. Leon MB; Nikolsky E; Cutlip DE; Mauri L; Liberman H; Wilson H; Patterson J; Moses J; Kandzari DE; JACC Cardiovasc Interv; 2010 Oct; 3(10):1043-50. PubMed ID: 20965463 [TBL] [Abstract][Full Text] [Related]
49. Clinical outcome of patients with de novo coronary bifurcation lesions treated with the Tryton Side Branch Stent. The SAFE-TRY prospective multicenter single arm study. Tarantini G; La Vecchia L; Galli M; Favero L; D'Amico G; Buja P; Russo F; Cabianca E; Napodano M; Musumeci G; Franceschini E; Grassi G; Pavei A; Bonmassari R; Cernetti C; Spedicato L; Caprioglio F; Reimers B; Isabella G Int J Cardiol; 2013 Oct; 168(6):5323-8. PubMed ID: 24007969 [TBL] [Abstract][Full Text] [Related]
50. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL; Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853 [TBL] [Abstract][Full Text] [Related]
51. First-in-man 1-year clinical outcomes of the Catania Coronary Stent System with Nanothin Polyzene-F in de novo native coronary artery lesions: the ATLANTA (Assessment of The LAtest Non-Thrombogenic Angioplasty stent) trial. Tamburino C; La Manna A; Di Salvo ME; Sacchetta G; Capodanno D; Mehran R; Dangas G; Corcos T; Prati F JACC Cardiovasc Interv; 2009 Mar; 2(3):197-204. PubMed ID: 19463426 [TBL] [Abstract][Full Text] [Related]
53. One-year outcome of patients with diabetes mellitus after percutaneous coronary intervention with three different revascularization strategies: results from the Diabetic Argentina Registry (DEAR). Mieres J; Fernandez-Pereira C; Risau G; Solorzano L; Pauletto R; Rodriguez-Granillo AM; Rubilar B; Stella P; Rodriguez AE Cardiovasc Revasc Med; 2012; 13(5):265-71. PubMed ID: 22796496 [TBL] [Abstract][Full Text] [Related]
54. Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis. Richardt G; Leschke M; Abdel-Wahab M; Toelg R; El-Mawardy M; Serruys PW; Silber S; Windecker S; Belardi JA; Neumann FJ; Widimsky P; ; JACC Cardiovasc Interv; 2013 Sep; 6(9):905-13. PubMed ID: 23954063 [TBL] [Abstract][Full Text] [Related]
55. In-stent restenosis: the gold standard has changed. Chin K EuroIntervention; 2011 May; 7 Suppl K():K43-6. PubMed ID: 22027726 [TBL] [Abstract][Full Text] [Related]
56. Unprotected left main coronary artery stenting with zotarolimus (Endeavor) drug-eluting stents: a single center retrospective experience. Simard T; Hibbert B; Chong AY; Ruchin P; Le May M; Labinaz M; Froeschl M; So D; Glover C; Marquis JF; O'Brien E Catheter Cardiovasc Interv; 2012 Aug; 80(2):E15-22. PubMed ID: 21805580 [TBL] [Abstract][Full Text] [Related]
57. Comparison of Drug-Eluting Balloon Followed by Bare Metal Stent with Drug-Eluting Stent for Treatment of de Novo Lesions: Randomized, Controlled, Single-Center Clinical Trial. Chae IH; Yoon CH; Park JJ; Oh IY; Suh JW; Cho YS; Youn TJ; Choi DJ J Korean Med Sci; 2017 Jun; 32(6):933-941. PubMed ID: 28480650 [TBL] [Abstract][Full Text] [Related]
58. Two-year follow-up of the Genous™ endothelial progenitor cell capturing stent versus the Taxus Liberté stent in patients with de novo coronary artery lesions with a high-risk of restenosis: a randomized, single-center, pilot study. Beijk MA; Klomp M; van Geloven N; Koch KT; Henriques JP; Baan J; Vis MM; Tijssen JG; Piek JJ; de Winter RJ Catheter Cardiovasc Interv; 2011 Aug; 78(2):189-95. PubMed ID: 21542109 [TBL] [Abstract][Full Text] [Related]
59. Comparison of six-year clinical outcome of sirolimus- and paclitaxel-eluting stents to bare-metal stents in patients with ST-segment elevation myocardial infarction: an analysis of the RESEARCH (rapamycin-eluting stent evaluated at Rotterdam cardiology hospital) and T-SEARCH (taxus stent evaluated at Rotterdam cardiology hospital) registries. Simsek C; Magro M; Boersma E; Onuma Y; Nauta S; Daemen J; Gaspersz M; van Geuns RJ; van der Giessen W; van Domburg R; Serruys P J Invasive Cardiol; 2011 Aug; 23(8):336-41. PubMed ID: 21828397 [TBL] [Abstract][Full Text] [Related]
60. Clinical and procedural predictors of suboptimal outcome after the treatment of drug-eluting stent restenosis in the unprotected distal left main stem: the Milan and New-Tokyo (MITO) registry. Takagi K; Ielasi A; Shannon J; Latib A; Godino C; Davidavicius G; Mussardo M; Ferrarello S; Figini F; Carlino M; Montorfano M; Chieffo A; Nakamura S; Colombo A Circ Cardiovasc Interv; 2012 Aug; 5(4):491-8. PubMed ID: 22851528 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]